FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit
This article was originally published in The Tan Sheet
Executive Summary
The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to take stock of its relationship with Congress and to re-evaluate its organizational structure.
You may also be interested in...
FDA Becomes An Agency Of “Directorates” Under Hamburg’s Reorganization
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the agency’s centers intact, but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.
Tyler's Departure As FDA Chief Counsel Leaves Another Chair To Fill
Ralph Tyler is leaving FDA 18 months after taking the helm as the agency's chief counsel.
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
John Taylor, counselor to FDA Commissioner Margaret Hamburg, will serve temporarily as second-in-command while Hamburg considers how to reorganize the agency's leadership following Principal Deputy Commissioner Josh Sharfstein's departure.